메뉴 건너뛰기




Volumn 23, Issue 7, 2009, Pages 626-630

The role of LHRH antagonists in the treatment of prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; DEGARELIX; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

EID: 67650904494     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (42)

References (25)
  • 1
    • 84928580276 scopus 로고
    • Studies on prostate cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
    • Huggins C, Hodges CV: Studies on prostate cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293, 1941.
    • (1941) Cancer Res , vol.1 , pp. 293
    • Huggins, C.1    Hodges, C.V.2
  • 2
    • 0014088849 scopus 로고
    • Treatment and survival of patients with cancer of the prostate
    • Veterans Administration Cooperative Urological Research Group
    • Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011, 1967.
    • (1967) Surg Gynecol Obstet , vol.124 , pp. 1011
  • 3
    • 0023726635 scopus 로고
    • Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group Studies
    • Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr 7:165, 1988. (Pubitemid 18225389)
    • (1988) NCI Monographs , Issue.7 , pp. 165-170
    • Byar, D.P.1    Corle, D.K.2
  • 4
    • 0029090784 scopus 로고
    • A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma
    • Casodex Study Group
    • Kalsary AV, Tyrrell CJ, Beacock C, et al: A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Eur Urol 28:215-222, 1995.
    • (1995) Eur Urol , vol.28 , pp. 215-222
    • Kalsary, A.V.1    Tyrrell, C.J.2    Beacock, C.3
  • 5
    • 0029882360 scopus 로고    scopus 로고
    • Randomised study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer
    • The Scandinavian Casodex Cooperative Group
    • Iversen P, Tveter K, Varenhorst E: Randomised study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol 30:93-98, 1996.
    • (1996) Scand J Urol Nephrol , vol.30 , pp. 93-98
    • Iversen, P.1    Tveter, K.2    Varenhorst, E.3
  • 6
    • 0035321536 scopus 로고    scopus 로고
    • Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: A systematic review
    • Schmitt B, Wilt TJ, Schellhammer PF, et al: Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: A systematic review. Urology 57:727-732, 2001.
    • (2001) Urology , vol.57 , pp. 727-732
    • Schmitt, B.1    Wilt, T.J.2    Schellhammer, P.F.3
  • 7
    • 58149170709 scopus 로고    scopus 로고
    • Twenty-five year evolution of medical hormonal therapy for prostate cancer
    • Moul JW: Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int 103:145-146, 2009.
    • (2009) BJU Int , vol.103 , pp. 145-146
    • Moul, J.W.1
  • 8
    • 0023226588 scopus 로고
    • Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist
    • Labrie F, Dupont A, Belanger A, et al: Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 138:804-806, 1987. (Pubitemid 17150766)
    • (1987) Journal of Urology , vol.138 , Issue.4 , pp. 804-806
    • Labrie, F.1    Dupont, A.2    Belanger, A.3    Lachance, R.4
  • 9
    • 0036088023 scopus 로고    scopus 로고
    • Hormonal therapy for prostate cancer: Past, present and future
    • el-Rayes BF, Hussain MH: Hormonal therapy for prostate cancer: Past, present and future. Expert Rev Anticancer Ther 2:37-47, 2002.
    • (2002) Expert Rev Anticancer Ther , vol.2 , pp. 37-47
    • El-Rayes, B.F.1    Hussain, M.H.2
  • 10
    • 0037299787 scopus 로고    scopus 로고
    • A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide acetate in men with prostate cancer
    • MacLeod DG, Zinner N, Tomera K, et al: A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 61(suppl 1):3-7, 2003.
    • (2003) Urology , vol.61 , Issue.SUPPL. 1 , pp. 3-7
    • MacLeod, D.G.1    Zinner, N.2    Tomera, K.3
  • 12
    • 84888534748 scopus 로고    scopus 로고
    • note
    • Lupron Depot 7.5 mg (package insert). Lake Forest, Ill; TAP Pharmaceuticals Inc; 2007.
  • 13
    • 1242341916 scopus 로고    scopus 로고
    • Targeting FSH in androgen-independent prostate cancer: Abarelix for prostate cancer progressing after orchiectomy
    • DOI 10.1016/j.urology.2003.09.045
    • Beer TM, Garzotto M, Eilers KM, et al: Targeting FSH in androgen-independent prostate cancer: Abarelix for prostate cancer progressing after orchiectomy. Urology 63:342-347, 2004. (Pubitemid 38234432)
    • (2004) Urology , vol.63 , Issue.2 , pp. 342-347
    • Beer, T.M.1    Garzotto, M.2    Eilers, K.M.3    Lemmon, D.4    Wersinger, E.M.5
  • 14
    • 44049099624 scopus 로고    scopus 로고
    • Gonadotropin-releasing hormone antagonist in the management of prostate cancer
    • Debruyne FM: Gonadotropin-releasing hormone antagonist in the management of prostate cancer. Rev Urol 6(suppl 7):S25-S32, 2004.
    • (2004) Rev Urol , vol.6 , Issue.SUPPL. 7
    • Debruyne, F.M.1
  • 15
    • 0035046991 scopus 로고    scopus 로고
    • The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
    • Tomera K, Gleason D, Gittelman M, et al: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165:1585-1589, 2001. (Pubitemid 32410246)
    • (2001) Journal of Urology , vol.165 , Issue.5 I , pp. 1585-1589
    • Tomera, K.1    Gleason, D.2    Gittelman, M.3    Moseley, W.4    Zinner, N.5    Murdoch, M.6    Menon, M.7    Campion, M.8    Garnick, M.B.9
  • 18
    • 0035944837 scopus 로고    scopus 로고
    • Gonadotropin-releasing-hormone-receptor antagonists
    • Huirne JAF, Lambalk CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358:1793-1803, 2001.
    • (2001) Lancet , vol.358 , pp. 1793-1803
    • Huirne, J.A.F.1    Lambalk, C.B.2
  • 19
    • 50849110501 scopus 로고    scopus 로고
    • Degarelix: A novel gonadotropin-releasing hormone (GnRH) blocker - Results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer
    • Van Poppel H, Tombal B, de la Rosette JM, et al: Degarelix: A novel gonadotropin-releasing hormone (GnRH) blocker - results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol 54:805-815, 2008.
    • (2008) Eur Urol , vol.54 , pp. 805-815
    • Van Poppel, H.1    Tombal, B.2    De La Rosette, J.M.3
  • 20
    • 53249121469 scopus 로고    scopus 로고
    • A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America
    • Gittelman M, Pommerville PJ, Persson BE, et al: A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 180:1986-1992, 2008.
    • (2008) J Urol , vol.180 , pp. 1986-1992
    • Gittelman, M.1    Pommerville, P.J.2    Persson, B.E.3
  • 21
    • 56649116179 scopus 로고    scopus 로고
    • The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    • Klotz L, Boccon-Gibod L, Shore ND, et al: The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531-1538, 2008.
    • (2008) BJU Int , vol.102 , pp. 1531-1538
    • Klotz, L.1    Boccon-Gibod, L.2    Shore, N.D.3
  • 22
    • 84888485838 scopus 로고    scopus 로고
    • Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group phase III study in prostate cancer patients
    • (abstract 537) Presented at the
    • Boccon-Gibod L, Klotz L, Schröder H, et al: Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group phase III study in prostate cancer patients (abstract 537). Presented at the 23rd Annual EAU Congress, Milan, Italy, 2008.
    • 23rd Annual EAU Congress, Milan, Italy, 2008
    • Boccon-Gibod, L.1    Klotz, L.2    Schröder, H.3
  • 23
    • 58149144740 scopus 로고    scopus 로고
    • Will GnRH antagonists improve prostate cancer treatment?
    • Huhtaniemi I, White R, McArdle C, et al: Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab 20:43-50, 2009.
    • (2009) Trends Endocrinol Metab , vol.20 , pp. 43-50
    • Huhtaniemi, I.1    White, R.2    McArdle, C.3
  • 24
    • 33646036678 scopus 로고    scopus 로고
    • FSH directly regulates bone mass
    • Sun L, Peng YZ, Sharrow AC, et al: FSH directly regulates bone mass. Cell 125:247-260, 2006.
    • (2006) Cell , vol.125 , pp. 247-260
    • Sun, L.1    Peng, Y.Z.2    Sharrow, A.C.3
  • 25
    • 84870960298 scopus 로고    scopus 로고
    • Available at Accessed March 20, 2009
    • American Cancer Society: How many men get prostate cancer? Available at http://www.cancer.org/. Accessed March 20, 2009.
    • How Many Men Get Prostate Cancer?


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.